Last reviewed · How we verify
Ketamine infusion
At a glance
| Generic name | Ketamine infusion |
|---|---|
| Also known as | Ketalar, Ketamine hydrochloride, hyperalgesia-blocker |
| Sponsor | Yale University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Electroencephalographic (EEG) Profils for Patients on Intravenous Ketamine.
- Management of Pain in Lumbar Arthrodesis (PHASE4)
- Neurobiology of Suicide (PHASE2)
- Ketamine Pharmacokinetics and Pharmacodynamics for Postpartum Depression and Pain After Cesarean Delivery (PHASE1)
- Ketamine + Cognitive Training for Suicidality in the Medical Setting (PHASE4)
- Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts (PHASE4)
- Erector Spinae Block Vs Ketamine-based Multimodal Analgesia Protocol in Lumber Decompressive Surgery (NA)
- Gamma Oscillations as a Prognostic Marker for Ketamine Therapy in Treatment Resistant Depression (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ketamine infusion CI brief — competitive landscape report
- Ketamine infusion updates RSS · CI watch RSS
- Yale University portfolio CI